Phase 1 Trial of CIT-013 in Immune-Mediated Inflammatory Diseases

The study evaluates immune mediated inflammatory diseases in a phase 1 setting. The primary objective is not specified in the source data. No secondary objectives are reported in the source data.

The sponsor did not provide this information. The available record indicates a study population that included healthy volunteers of both sexes, with an age range corresponding to children and adolescents, but no total participant count, selection details, lifestyle considerations, or additional inclusion or exclusion criteria were reported.

The study is a phase 3 clinical trial in immune mediated inflammatory diseases. The overall trial duration is estimated from 2026-05-20 to 2026-08-07. The protocol includes an inclusion screening visit to assess eligibility, followed by study visits during participation and an end-of-study visit to complete final assessments. The expected length of participant involvement is not specified. Early termination from the study may occur if eligibility criteria are not met or are no longer satisfied.

No investigational or comparator treatment was specified in the source data. No pharmaceutical form, dosage, route, frequency of administration, dosing schedule, or compliance monitoring information was provided.

Efficacy will be assessed in a immune mediated inflammatory diseases population during the phase 3 clinical trial. The source data do not specify the efficacy parameters, assessment methods, measurement tools, or evaluation timepoints.